Table 1 Patient baseline characteristics.
Overall population (N = 146) | TTF1 low cohort (n = 49) | TTF1 middle cohort (n = 47) | TTF1 high cohort (n = 50) | |
|---|---|---|---|---|
Age | ||||
Years | 68.2 ± 8.9 | 69.4 ± 7.9 | 67.4 ± 9.9 | 67.6 ± 9.0 |
Sex | ||||
Male | 79 (54.1%) | 27 (55.1%) | 24 (49.0%) | 29 (58.0%) |
Female | 67 (45.9%) | 22 (44.9%) | 23 (46.9%) | 21 (42.0%) |
ECOG performance score | ||||
>1 | 11 (7.5%) | 4 (8.2%) | 3 (6.4%) | 4 (8.0%) |
Karnofsky performance status scale | ||||
>80 | 44 (30.1%) | 17 (34.7%) | 14 (29.8%) | 13 (26.0%) |
BSA, m2 | 1.79 ± 0.21 | 1.77 ± 0.23 | 1.81 ± 0.20 | 1.79 ± 0.20 |
BMI, kg/m2 | 24.2 ± 4.2 | 24.0 ± 4.5 | 23.8 ± 3.97 | 24.8 ± 4.1 |
CA19.9 (μ/ml) | ||||
≤40 μ/ml | 34 (23.3%) | 10 (20.4%) | 8 (17.0%) | 16 (32.0%) |
>40–≤100 μ/ml | 8 (5.5%) | 2 (4.1%) | 5 (10.6%) | 1 (2.0%) |
>100–≤500 μ/ml | 21 (14.4%) | 10 (20.4%) | 4 (8.5%) | 7 (14.0%) |
>500 μ/ml | 83 (56.8%) | 27 (55.1%) | 30 (63.8%) | 26 (52.0%) |
